ation with a mean 3.6 ml/min/year decline of Ccr. These preliminary results have potential important Background. Hypertension occurs commonly and early implications for cardiovascular and renal protection in in the natural history of autosomal dominant poly-ADPKD. cystic kidney disease (ADPKD), affecting both renal and patient outcome. Activation of the renin-angioten-Key words: ACE inhibitors; left ventricular hypersin-aldosterone system due to cyst expansion and local trophy; polycystic kidney disease renal ischaemia plays an important role in the development of ADPKD related hypertension and left ventricular hypertrophy (LVH ), a known important risk
Introduction
factor for cardiovascular morbidity and mortality. The aim of this study was to investigate the effects of an angiotensin converting enzyme (ACE) inhibitor, enala-Autosomal dominant polycystic kidney disease pril, on renal function, blood pressure and LVH in (ADPKD) is the most common hereditary renal dishypertensive ADPKD patients.
order and accounts for 8-10% of the end-stage renal Methods. Fourteen hypertensive ADPKD patients (11 disease ( ESRD) population in the US [1] . men, 3 women; mean age: 40 years) were included in Hypertension occurs commonly in ADPKD patients the study. All patients had LVH and creatinine clear-with an incidence of approximately 60% before the ance (Cer) greater than 50 ml/min/1.73 m2. The renal function has become impaired [2] . Left ventricular hypertrophy (LVH ) occurs frequently in hypertenspatients were followed for 7 years on enalapril therapy.
ive ADPKD patients, with a prevalence of 48% [3] . It The effects of enalapril on renal function, blood presis well-known that both hypertension and LVH are sure and LVH were investigated. associated with an accelerated rate of renal functional Results. Baseline measurements of mean arterial presdeterioration and are important risk factors for cardiosure (MAP), Ccr and left ventricular mass index vascular death, the most frequent cause of mortality (LVMI ) were 110±2 mmHg, 84±6 ml/min/1.73 m2 in ADPKD patients [4, 5] . and 146±4 g/m2, respectively. After one year of enalaActivation of the renin-angiotensin-aldosterone pril therapy there was a significant decrease in MAP system (RAAS ) due to cyst expansion and local renal (94±3 mmHg, P<0.005) which remained stable until ischaemia has been proposed to play an important role the end of the study at 7 years (94±1 mmHg, P<0.005 in the development of hypertension in ADPKD [6 ] . vs baseline). There was also a significant decrease in Several studies have shown that the RAAS is activated LVMI (131±6 g/m2, P<0.05) after year 1 which conin ADPKD patients with established hypertension tinued to decrease until the end of the study reaching prior to loss of renal function [6, 7] . 98±6 g/m2 (P<0.01 vs year 1 and baseline). Although
The aim of the present 7 year study was to investigate Ccr remained stable after year 1, a significant decrease the effects of an angiotensin converting enzyme (ACE) was observed after 7 years of follow-up (59±6 ml/min, inhibitor, enalapril, on renal function, blood pressure P<0.001 vs year 1 and baseline).
and LVH in hypertensive ADPKD patients. Conclusions. ACE inhibition in hypertensive ADPKD patients provided long-term reversal of LVH in associ-effect of enalapril on renal function and LVH. The patients Changes over time of the three parameters (MAP, CCr, and LVMI ) were analysed with signed-rank analysis. have been randomized into moderate and intensive blood pressure control groups. In the moderate blood pressure Statistical significance was defined as P<0.05; significant P values are reported in the text. Variables are reported as the control group, the target mean arterial pressure (MAP) is 100-107 mmHg, whereas in the intensive blood pressure mean±standard error of the mean (SEM ). control group the target MAP is less than 92 mmHg. Herein, we report the results of the first 14 patients who have finished
Results
the study after 7 years of enalapril treatment. Since the results of the moderate versus intensive blood pressure control groups are not available until the end of the study, The demographic characteristics, mean arterial presonly the effect of enalapril on blood pressure, renal function sures, creatinine clearances and left ventricular mass and LVH for all 14 patients will be reported.
indexes of the 14 patients are shown on Table 1 and all had LVH ( left ventricular mass index (LVMI ) greater LVMI (131±6 mmHg, P<0.05), while the Ccr than 125 g/m2 for males and greater than 110 g/m2 for remained stable. After the end of 7 years, there was females). Echocardiographic studies were performed at base-an additional decrease in LVMI (98±6 g/m2) which line and at year 1 using a Honeywell ultraimager with 2.25-was statistically significant compared to baseline and or 3.5-MHz mechanical sector scanners. In year 7, the year 1 (P<0.01) ( Figure 1 ). The MAP remained stable echocardiographic studies were performed with Hewlett from year 1 to year 7, whereas there was a significant Packard Sonos 2500 or 5500 imaging systems using 2.5 to decrease in Ccr (59±6 ml/min/1.73 m2, P<0.001) 4.0-MHz phased array transducers. Two-dimensional images compared to baseline and year 1 ( Table 1) .
were used to direct the M-mode sweep. Measurements were made according to the conventions of the American Society of Echocardiography [8, 9] . LVMI was calculated using the Discussion Penn equation and corrected for body surface area [10] .
After withdrawal from antihypertensive medications and a washout phase of 2-4 weeks, the patients were started It is well-known that hypertension has a negative effect enalapril with a daily maximum dose of 40 mg orally. The both on kidney and patient survival in patients with patients were followed for 7 years on enalapril therapy. Six chronic renal disease [11, 12] . ADPKD patients with of the 14 patients only received enalapril during the 7 years hypertension have a faster progression to ESRD than of the study. As second-line therapy, eight patients also their normotensive counterparts [4] . In addition, LVH received hydrochlorothiazide, six patients clonidine, five is a blood pressure-independent risk factor for cardiopatients spironolactone and three patients furosemide. In the vascular morbidity and mortality both in essential first year of the study, four patients received amlodipine as hypertension and in ESRD [13, 14] . In a 10-year followinitial therapy as part of a 1-year comparison study with up study of patients with essential hypertension, Koren enalapril. The total period of amlodipine therapy however comprised only 5% of the 7 year follow-up of all 14 patients. et al. [13] showed that cardiovascular deaths occurred Here we are reporting a 7 year follow-up of 14 ADPKD patients with hypertension and LVH. ACE inhibition with enalapril as initial therapy caused a significant decrease both in MAP and LVMI in our hypertensive ADPKD patients. After 7 years of enalapril therapy, a significant decrease in Ccr was observed. Administration of ACE inhibitors may cause an initial fall in GFR, particularly in ADPKD patients with any initial fall in GFR, however, the slope of the decrease in GFR may stabilize and result in a longterm beneficial effect on progression of chronic renal in a higher proportion of patients with than without LVH (14% compared with 0.5%, P<0.001). Similarly, diseases. In the present study, there was no statistically significant difference in Ccr after 1 year of enalapril cardiovascular complications are more common in ADPKD patients with hypertension and LVH [5] . treatment. The statistically significant decrease that was seen after 7 years of follow-up could therefore be These facts underline the importance of the treatment of both hypertension and LVH to increase kidney and related primarily to the natural progression of the disease. The mean annual decrease of creatinine clearpatient survival in ADPKD.
There are several experimental and clinical observa-ance in our patients was 3.6 ml/min. In the Modification of Diet in Renal Disease (MDRD) study, tions that show an increased activity of the RAAS in ADPKD patients. Graham and Lindop [15] demon-patients with ADPKD have been reported to average a GFR loss of 6 ml/min/year [23] . In contrast to strated that kidneys obtained from nephrectomy or autopsy specimens of patients with ADPKD showed present study, however, the MDRD study was performed in ADPKD patients with advanced renal disincreased renin in juxtaglomerular apparatus as well as renin granules along the afferent arteriole and within ease (GFR <55 ml/min) and the mean follow-up period was only 2.2 years. Since our patients' mean cyst walls. Hypertensive ADPKD patients with normal renal function have significantly higher plasma renin age after 7 years follow-up was 47 years, at an annual rate of 3.6 ml/min/1.73 m2 renal functional loss, endactivity and plasma aldosterone concentration while supine or upright and after captopril administration, stage renal disease would not be expected to occur until nearly 70 years old. In contrast, hypertensive as compared to patients with essential hypertension and similar blood pressures and renal function [6 ] .
ADPKD patients with uncontrolled blood pressure and LVH have been observed to have ESRD at age Angiotensin II has several potential detrimental effects on the progression of renal disease. Apart from 44 years [4] . Therefore, early treatment of ADPKD patients may afford important protection of renal as its systemic vasoconstrictor effect, angiotensin II also has a more pronounced effect on the efferent arteriole well as cardiovascular function.
In conclusion, ACE inhibition with enalapril in than the afferent arteriole, thus causing intraglomerular pressure to rise. Moreover, angiotensin II, as a growth hypertensive ADPKD patients provided long-term control of blood pressure, reversal of LVH and perhaps factor, may exert direct effects on cell proliferation and growth and also may stimulate the expression of other a slowing of renal functional loss. These preliminary results have potential important implications for vasoactive factors and cytokines, such as endothelin, transforming growth factor b 1 ( TGF-b 1 ), basic cardiovascular and renal protection in ADPKD patients. Optimal results may necessitate treatment of fibroblast growth factor (bFGF ) and platelet-derived growth factor (PDGF ). These latter effects would lead ADPKD patients early in one course of their disease. to increased production of extracellular matrix components and promote glomerular and interstitial infiltration of inflammatory cells [16 ] . Angiotensin II has References also been suggested to be one of the major pathogenetic and protein synthesis in cardiac myocytes in both 3. Chapman AB, Johnson AM, Rainguet S, Hossack K, Gabow P,
